Standardization of the teratoma assay for analysis of pluripotency of human ES cells and biosafety of their differentiated progeny
Teratoma tumor formation is an essential criterion in determining the pluripotency of human pluripotent stem cells. However, currently there is no consistent protocol for assessment of teratoma forming ability. Here we present detailed characterization of a teratoma assay that is based on subcutaneo...
Saved in:
Published in | PloS one Vol. 7; no. 9; p. e45532 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
25.09.2012
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Teratoma tumor formation is an essential criterion in determining the pluripotency of human pluripotent stem cells. However, currently there is no consistent protocol for assessment of teratoma forming ability. Here we present detailed characterization of a teratoma assay that is based on subcutaneous co-transplantation of defined numbers of undifferentiated human embryonic stem cells (hESCs) with mitotically inactivated feeder cells and Matrigel into immunodeficient mice. The assay was highly reproducible and 100% efficient when 100,000 hESCs were transplanted. It was sensitive, promoting teratoma formation after transplantation of 100 hESCs, though larger numbers of animals and longer follow-up were required. The assay could detect residual teratoma forming cells within differentiated hESC populations however its sensitivity was decreased in the presence of differentiated cells. Our data lay the foundation, for standardization of a teratoma assay for pluripotency analysis. The assay can also be used for bio-safety analysis of pluripotent stem cell-derived differentiated progeny. |
---|---|
Bibliography: | Conceived and designed the experiments: Michal Gropp BER NBZ. Performed the experiments: Michal Gropp VS Miri Gov YG. Analyzed the data: Michal Gropp VS GV JK NBZ BER. Contributed reagents/materials/analysis tools: HK LM MI. Wrote the manuscript: Michal Gropp BER. Competing Interests: BR is the CSO and holds shares in CellCure Neurosciences Ltd. VS, M. Gov, LM and NBZ were employees of CellCure Neurosciences Ltd. when the study was performed. M. Gropp was funded for this study by CellCure Neurosciences Ltd. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0045532 |